Avertin Anesthetic (Avertin, 2,2,2-Tribromoethanol): Overview, Applications, and Experimental Precautions

Avertin is an injectable laboratory animal anesthetic that uses 2,2,2-tribromoethanol (tribromoethanol, TBE) as the active ingredient. It is commonly used to induce short-duration general anesthesia in rodents such as mice. Induction is relatively rapid and the method is less dependent on specialized anesthesia equipment; however, anesthetic depth and duration are highly sensitive to preparation quality, light-protected cold storage, expiration management, and intraperitoneal (IP) injection technique. In research settings, standardizing preparation and record-keeping, implementing strict peri-anesthetic support and monitoring, and proactively evaluating potential confounders related to study endpoints can reduce anesthesia-associated systematic error and improve animal welfare and data reproducibility.

Keywords: Avertin; tribromoethanol; mouse anesthesia; intraperitoneal injection; peri-anesthetic management; quality control; adverse reactions

I. Definition and Methodological Positioning of Avertin in Experimental Research

1.1 Basic definition

Avertin typically refers to an injectable anesthetic centered on tribromoethanol, with intraperitoneal injection (intraperitoneal injection, IP) as the classic administration route to induce general anesthesia in rodents. Within the experimental animal anesthesia toolbox, it is often used as one option for short-duration procedures where workflow standardization is feasible and operative time is predictable.

1.2 Application positioning and methodological boundaries

(1) Suitable for short-duration, one-time, or low-frequency anesthesia needs.

(2) Not recommended as a routine approach for long, complex surgeries or high-frequency repeated anesthesia.

(3) More dependent than many ready-to-use inhalational anesthesia workflows on the full chain of “preparation consistency—storage stability—injection technique—peri-anesthetic management,” and should be incorporated into the laboratory quality system as an SOP.

II. Physicochemical Properties and the Experimental Implications of Pharmacodynamic Performance

Item	Information
Name	Tribromoethanol
Aliases	2,2,2-tribromoethanol; tribromoethyl alcohol; Bromethol
Molecular formula	Br₃CCH₂OH
Molecular weight	282.76
Appearance	White solid powder; heavy (density > iron)
Density	2.866 g/cm³
Melting point	73–79°C
Boiling point	199°C (760 mmHg)
Flash point	99.7°C
Vapor pressure	0.0879 mmHg (25°C)
InChI	InChI=1/C2H3Br3O/c3-2(4,5)1-6/h6H,1H2
Hazard symbol	Xn: Harmful
Risk phrases	R22; R36/37/38;

2.1 Stability and degradation-related sources of bias

Tribromoethanol is sensitive to light exposure and temperature conditions. Degradation may reduce active content and may also increase irritating impurities. In research contexts, such changes commonly manifest as:

(1) Prolonged induction time or increased inter-individual variability, resulting in higher within-group variance.

(2) Fluctuations in maintenance duration, compromising the consistency of sampling time windows.

(3) Increased peritoneal irritation, potentially introducing local inflammation and confounding immune-, inflammation-, and metabolism-related endpoints.

(4) Pronounced batch effects: different batches of working solution may produce systematic shifts, reducing cross-batch comparability.

2.2 Route of administration and the particularities of the peritoneal environment

Intraperitoneal injection is highly sensitive to injection placement and solution quality. Osmolality, irritating impurities, and injection volume can all affect peritoneal tolerability. Compared with inhalational anesthesia, IP injection is difficult to titrate in real time to adjust depth, placing higher demands on upfront dose calibration and process monitoring.

III. Primary Use Cases and Situations Where Use Is Not Recommended

3.1 Common use cases

(1) Short procedures: brief imaging acquisition, rapid immobilization, short surgical exposure, and simple manipulations.

(2) Terminal tissue collection: completing euthanasia and sampling within a rapid, controllable time window.

(3) Limited equipment availability: an alternative when a stable inhalational anesthesia system is unavailable, while still requiring warming and monitoring capacity.

3.2 Not recommended

(1) Procedures requiring long-term maintenance of stable anesthetic depth.

(2) Study designs requiring repeated anesthesia.

(3) Studies where peritoneal, mesenteric, peritonitis-related, or gastrointestinal reactions are primary endpoints.

(4) Physiology studies requiring high-precision control of respiration, circulation, blood gases, and temperature.

IV. Key Precautions to Implement in Research Experiments

4.1 Preparation and batch management

(1) Light protection: avoid light throughout preparation, aliquoting, and short-term holding; use amber containers or wrap with aluminum foil.

(2) Cold-chain control: store working solution under defined refrigerated or frozen conditions; avoid prolonged room-temperature exposure; repeated “take out—return” cycles on the bench are discouraged.

(3) Small-volume aliquots: aliquot to single-use or single-day volumes to reduce post-opening light exposure, contamination, adsorption loss, and cumulative degradation.

(4) Sterile filtration: 0.22 µm filtration followed by aliquoting is recommended; for cytokine-, inflammation-, or infection-sensitive studies, nonspecific inflammation risk from contamination must be rigorously avoided.

(5) Appearance and physicochemical checks: discard immediately if darkening, turbidity, precipitates/crystals, or abnormal odor is observed.

(6) Record system: at minimum, record raw material lot number, preparation date, aliquot specification, storage conditions, freeze–thaw cycles, discard date, and operator; if abnormal anesthesia phenotypes or deaths occur, records are the key evidence chain for traceability and corrective action.

(7) Pre-validation of batches: before formal experiments, test a small number of animals to confirm induction time, anesthetic depth, and recovery time are within predefined acceptable ranges, preventing failed batches from entering the main study.

4.2 Consistency control of dose, body weight, and administration

(1) Weigh animals immediately before dosing; use a single unit system and a single conversion table to avoid systematic bias from estimated body weights.

(2) Generate injection volumes using a standardized table or calculation template, with second-person verification or electronic record locking to reduce manual conversion errors.

(3) Within a study batch, keep animal age, body-weight range, and husbandry conditions as consistent as possible; large differences in adiposity increase variance in anesthetic phenotype and reduce statistical power.

(4) Consistent solvent exposure for combined treatments: if any group involves exposure to solvents such as DMSO, ensure all groups have the same final solvent concentration to prevent solvent-driven confounding effects on cardiorespiratory function or behavioral stress.

4.3 Technical key points for intraperitoneal injection and recognition of failures

(1) Standardize injection site and angle: establish unified laboratory specifications for injection site, needle direction, and depth to reduce operator variability.

(2) Avoid organ injury: match needle gauge to animal weight; aspiration after needle placement should not yield blood or urine; if abnormal aspiration occurs, stop injection and handle according to institutional procedures.

(3) Control injection speed and volume: overly rapid injection increases reflux risk, local pressure, and pain responses; excessive volume increases abdominal discomfort and may affect respiratory excursion.

(4) Recognize failure patterns: subcutaneous bulging, leakage, immediate intense reactions, or marked abdominal tension suggest non-IP delivery or excessive formulation irritancy; such individuals should not be directly included in key endpoint analyses and should be handled according to predefined exclusion criteria.

(5) Training and consistency: include success rate, failure rate, and complication recording as training metrics; in multi-operator environments, procedural consistency directly determines within-group noise.

4.4 Peri-anesthetic monitoring and supportive measures

(1) Temperature management: hypothermia during anesthesia prolongs recovery and increases mortality risk; use a thermostatic warming pad with an insulating layer to prevent thermal injury.

(2) Respiratory monitoring: continuously observe respiratory rate and depth; if shallow/slow breathing, irregular rhythm, cyanosis, or complete loss of reflexes with respiratory depression occurs, initiate emergency procedures immediately and stop further interventions.

(3) Standardize anesthetic depth assessment: use toe-pinch reflex, muscle tone, and respiratory parameter changes to create graded records; fix assessment time points within the same study batch to avoid phase mismatch caused by different assessment timing.

(4) Eye protection: for slightly longer procedures, apply ophthalmic ointment to prevent corneal drying and postoperative corneal injury.

(5) Fluids and moisture: during prolonged waiting or procedures, address dehydration risk and provide supportive fluids according to institution-approved protocols.

(6) Analgesia compliance: for incisions, organ exposure, or invasive procedures, implement analgesia as approved by animal ethics; pain and stress can alter the HPA axis, cytokine profiles, and immune cell distribution, affecting interpretation.

4.5 Recommendations for confound control related to study endpoints

(1) Inflammation/immune endpoints: Avertin-associated peritoneal irritation may induce local or systemic inflammatory changes; avoid using peritoneal tissue inflammation as a primary endpoint, or mitigate confounding via adequate controls and histological validation.

(2) Metabolic endpoints: anesthesia and hypothermia can alter glucose homeostasis, lipid metabolism, and hormone levels; standardize the interval of “dosing—anesthesia qualification—sampling” and keep it identical across groups.

(3) Blood flow/vascular function endpoints: differences in anesthetic depth affect blood pressure, heart rate, and peripheral perfusion, influencing outputs in ischemia–reperfusion and angiogenesis models; establish basic physiologic observation records and use them as quality-control information.

(4) Pharmacodynamics and pharmacokinetics endpoints: anesthesia regimens can affect hepatic/renal blood flow and metabolic clearance; specify the anesthesia method clearly in the Methods section and ensure intergroup consistency.

V. Common Abnormal Findings and Cause Analysis

5.1 Delayed induction or insufficient anesthesia

(1) Reduced potency of working solution or storage beyond expiration.

(2) Dose conversion errors or inaccurate body-weight measurement.

(3) Injection failure: not delivered into the peritoneal cavity or leakage occurred.

(4) High animal stress level causing unstable cardiorespiratory status.

5.2 Excessive depth and delayed recovery

(1) Overdose or inappropriate supplementation.

(2) Insufficient warming leading to hypothermia.

(3) Additive inhibitory effects from concomitant medications.

(4) Abnormal health status or occult disease reducing anesthetic tolerance.

5.3 Peritoneal complications or postoperative abnormalities

(1) Increased formulation irritancy, often associated with degradation, excessive concentration, or contamination.

(2) Needle injury or inadvertent organ entry leading to peritoneal inflammation.

(3) Repeated use leading to cumulative chronic peritoneal reactions that affect subsequent readouts.

VI. Aladdin-Related Products

Product Category	Catalog No.	Product Name	Grade and Purity	Intended Use Positioning
Anesthetic	R1511178	Ready-to-use Avertin (Mouse)	BioReagent, ready-to-use, sterile, 1.25%	A finished Avertin anesthesia option for short-duration intraperitoneal anesthesia in mice; minimizes on-site preparation variability and batch-to-batch fluctuation, facilitating a fixed induction and sampling time window.
Anesthetic	R1511179	Ready-to-use Avertin (Rat)	BioReagent, ready-to-use, sterile, 2.5%	A finished Avertin anesthesia option for short-duration intraperitoneal anesthesia in rats; reduces fluctuations in anesthetic depth and duration caused by preparation and storage variability.
Anesthetic	R1511177	Avertin (Ready-to-Use, for Rabbit)	BioReagent, ready-to-use, sterile	A finished Avertin anesthesia option for short-duration anesthesia workflows in rabbits; facilitates standardized peri-anesthetic support and monitoring.
Anesthetic	A1511180	Avertin (Concentrate)	BioReagent, sterile, 1.0 g/mL	A concentrated stock solution for preparing Avertin working solution; supports SOP-based aliquoting, light-protected cold storage, and expiry management, enabling batch pre-validation and traceable records.
Solvent	A103418	tert-Amyl alcohol	≥98%	One of the commonly used solvent systems for Avertin preparation; used to dissolve and prepare tribromoethanol working solution, suitable for method exploration or non-critical batch preparation.
Solvent	A103417	tert-Amyl alcohol	≥99%	A higher-purity solvent option for preparing Avertin working solution; reduces the risk of peritoneal irritation and anesthetic variability associated with impurity introduction.
Solvent	A103416	tert-Amyl alcohol	Standard for GC, ≥99.5%(GC)	For methodological validation of Avertin preparation or establishing anesthesia protocols with stricter solvent-purity baselines; suitable as a batch-consistency reference.
Solvent	A103419	tert-Amyl alcohol	Anhydrous Grade, ≥99%	For use cases requiring control of water content during Avertin working-solution preparation; reduces uncertainty in dissolution and stability attributable to moisture.
Buffer	P492453	PhosphateBuffered Saline（PBS）20X concentrate	sterile	A standard basic buffer used in Avertin-related workflows; can be used for peri-anesthetic rinsing, instrument/tissue handling, or sterile requirements in solution preparation.
Buffer	P274233	PhosphateBuffered Saline（PBS）20X concentrate,PH 7.5	Ultra pure	A high-cleanliness buffer choice for sampling and specimen handling in Avertin-related workflows; helps reduce impurity background interference with downstream endpoints.
Buffer	T494526	PhosphateBuffered Saline（PBS）1X concentrate	1X,sterile,pH7.2-7.4	Ready-to-use sterile PBS for post-Avertin sampling and peri-anesthetic procedures; reduces on-site preparation error and improves workflow consistency.
Inorganic Salt	C111547	Sodium chloride	Suitable for molecular biology, ≥99.5%(AT)	A salt choice for buffer systems used in molecular assay-related sample handling after Avertin anesthesia; helps reduce background effects from impurities on downstream molecular readouts.
Inorganic Salt	C111549	Sodium chloride	PrimorTrace™, ≥99.99% metals basis	A salt choice for metal-ion–sensitive experimental systems after Avertin anesthesia; reduces potential interference from trace metals on functional readouts.
Inorganic Salt Solution	S433733	Sodium chloride solution	0.9% in water, BioReagent Plus, suitable for cell culture	A ready-to-use isotonic saline option for peri-anesthetic and sampling workflows related to Avertin anesthesia; reduces weighing/preparation error and improves batch consistency.

Avertin can be suitable for short-duration rodent procedures, but anesthetic consistency and safety are constrained by preparation and storage quality, batch records and pre-validation, standardized intraperitoneal injection technique, and peri-anesthetic monitoring/support. In research applications, it is recommended to manage Avertin within a traceable quality system, proactively identifying and controlling confounders to reduce anesthesia-associated noise in effect size and statistical power. For non-matching study scenarios, inhalational anesthesia with stronger controllability or standardized combined injectable regimens should be prioritized to meet animal welfare and data reliability requirements.

For more related articles, please see below:

[1] Anesthesia and execution of experimental animals

[2] Comparative experiments on the surface anesthetic effects of local anesthetics

[3] Experiments on the vertebral anesthetic action of procaine

[4] Experimental effects of ketamine and sodium thiopental on the respiratory and circulatory systems of rabbits